Fig. 1 · Structure

Documents & Downloads

Pralatrexate

Cat. No. A11522 CAS 146464-95-1

DHFR inhibitor

Pralatrexate is an antifolate (a folate analogue metabolic inhibitor) designed to accumulate preferentially in cancer cells.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
DHFR

Cellular Effect

Cell Line Activity Value Description Reference
KB IC50 0.47 nM Antiproliferative activity against human KB cells expressing human RFC/FR-alpha/PCFT assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue assay [PMID: 29425443]
KB IC50 0.47 nM Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay [PMID: 24111942]
KB IC50 1.94 nM Antiproliferative activity against human KB cells expressing human RFC/FR-alpha/PCFT assessed as reduction in cell viability measured after 96 hrs in presence of folic acid by Cell-Titer Blue assay [PMID: 29425443]
KB IC50 1.94 nM Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay in presence of folic acid [PMID: 24111942]
R2 IC50 57 nM Growth inhibition of Chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTiter-blue assay [PMID: 24111942]
R2 IC50 819 nM Cytotoxicity in RFC-null Chinese hamster R2 cells assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue assay [PMID: 29425443]

In Vitro Studies

Pralatrexate produced clear concentration-dependent inhibition of recombinant human DHFR in a cell-free system, with an apparent inhibition constant of 45 nM. In PC3 prostate cancer cells, exposure to increasing concentrations for 72 h followed by compound-free medium for 48 h yielded an MTT cell viability IC50 of 0.01±0.002 μM. In RH4 cells cultured for 96 h, Pralatrexate exhibited the lowest mean IC50 (0.3712 nM) and maximal growth inhibition (nearly 100%) of all tested drugs. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Pralatrexate inhibition of recombinant human DHFR

Biochemical assay · recombinant human DHFR [1]

In a cell-free system containing recombinant human DHFR, pralatrexate produced clear concentration-dependent inhibition of activity, with an apparent inhibition constant of 45 nM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
apparent inhibition constants (Ki app) of DHFR inhibitionKi app 45 nM[1]

Literature-Reported Treatment Conditions

Method
cell-free system
Reported limits
Not stated in the sentences used: dose, schedule, vehicle.
Methods and source locations

Compound reported in the paper: Pralatrexate

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Enzyme activity assays (S5); Results (S29, S30, S31, S33, S34)

apparent inhibition constants (Ki app) of DHFR inhibition: apparent inhibition constants (Ki app) of DHFR inhibition; comparator: absence of pralatrexate — Results (S31, S33, S34)

Cell viability response in prostate cancer cells

Cell-based study · prostate cancer cell line PC3 [2]

PC3 prostate cancer cells were exposed to increasing concentrations of Pralatrexate for 72 h, followed by compound-free medium for 48 h. Cell viability assessed by MTT assay yielded an IC50 of 0.01±0.002 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viability; MTT assayIC50 PC3; 72 h exposure: IC50 0.01±0.002 μM[2]

Literature-Reported Treatment Conditions

Treatment concentration
increasing concentrations
Exposure duration
72 h; compound-free medium for 48 h
Method
exposed to pralatrexate
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Pralatrexate

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Cytotoxicity assays (S5, S7, S9, S11, S12); Results > Single-agent antiproliferative effects (S34, S35); Table 1 legend (S102)

cell viability; MTT assay: cell viability; MTT assay; comparator: untreated cells — Materials and methods > Cytotoxicity assays (S5); Results > Single-agent antiproliferative effects (S35); Table 1 legend (S102)

Growth inhibition in cultured tumor cells

Cell-based study · RH4 cells [3]

RH4 cells were cultured with increasing concentrations of Pralatrexate for 96 h, with metabolically active cells measured. Pralatrexate exhibited the lowest mean IC50 (0.3712 nM) and maximal growth inhibition (nearly 100%) of all tested drugs.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
number of metabolically active cellsIC50 RH4 cells; 96 h: mean IC50 0.3712 nM[3]

Literature-Reported Treatment Conditions

Exposure duration
96 h
Method
culturing RH4 cells in the presence of increasing concentrations
Reported limits
Not stated in the sentences used: dose, vehicle, control.
Methods and source locations

Compound reported in the paper: Pralatrexate

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > FP-RMS cell lines are sensitive to pralatrexate (S323, S324)

number of metabolically active cells: number of metabolically active cells — Results > FP-RMS cell lines are sensitive to pralatrexate (S323, S324)

In Vivo Studies

In SCID/beige mice bearing subcutaneous RH4 xenograft tumors, intraperitoneal Pralatrexate at 60 mg/kg, administered 2×/week for 2 weeks, induced complete tumor regression in all mice in the cohort within 2 weeks compared with vehicle control. Regressed tumors eventually recurred after Pralatrexate treatment ended. [3]

Tumor regression and recurrence in a xenograft model

Animal study · SCID/beige mice; subcutaneous xenograft tumors derived from RH4 cells [3]

RH4 cells were implanted into the flanks of ten SCID/beige mice per treatment group; pralatrexate (60 mg/kg, 2×/week for 2 weeks). Pralatrexate induced complete tumor regression in all mice in this cohort within two weeks. Once pralatrexate treatment was terminated, however, regressed tumors eventually recurred.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volumeReported result RH4 cells were implanted into the flanks of ten SCID/beige mice per treatment group; pralatrexate (60 mg/kg, 2×/week for 2 weeks). Pralatrexate induced complete tumor regression in all mice in this cohort within two weeks. Once pralatrexate treatment was terminated, however, regressed tumors eventually recurred.[3]

Conditions shared by the study groups

Route
intraperitoneal
Treatment course
2×/week for 2 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Pralatrexate 60 mg/kgvehicle control (1x /week for 10 weeks)RH4 cells were implanted into the flanks of ten SCID/beige mice per treatment group; pralatrexate (60 mg/kg, 2×/week for 2 weeks). Pralatrexate induced complete tumor regression in all mice in this cohort within two weeks. Once pralatrexate treatment was terminated, however, regressed tumors eventually recurred.[3]
Pralatrexate 60 mg/kg
Model: SCID/beige mice; subcutaneous xenograft tumors derived from RH4 cells
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Pralatrexate

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > FP-RMS cell lines are sensitive to pralatrexate (S335); Results > FP-RMS tumors are sensitive to pralatrexate (S347, S353, S354)

Tumor volume: Tumor volume; comparator: vehicle control (1x /week for 10 weeks) — Results > FP-RMS cell lines are sensitive to pralatrexate (S335); Results > FP-RMS tumors are sensitive to pralatrexate (S347, S353, S354)

Pralatrexate 60 mg/kg · Results > FP-RMS tumors are sensitive to pralatrexate (S347, S353, S354)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 146464-95-1
Applications DHFR inhibitor
Formula C23H23N7O5
Molecular Weight 477.47
Synonyms PDX; 10-Propargyl-10-deazaaminopterin; D05589
SMILES
C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 27 mg/mL (56.55 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Izbicka E, Diaz A, Streeper R, et al. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. Cancer Chemother Pharmacol (2009). PMID: 19221750 DOI: 10.1007/s00280-009-0954-4 Source material
  2. [2] Serova M, Bieche I, Sablin MP, et al. Single agent and combination studies of pralatrexate and molecular correlates of sensitivity. Br J Cancer (2011). PMID: 21179031 DOI: 10.1038/sj.bjc.6606063 Source material
  3. [3] Zimmerman SP, Delaney CD, Lau BK, et al. Fusion-positive rhabdomyosarcoma oncofusions share a common interactome. Nat Commun (2026). PMID: 42209514 DOI: 10.1038/s41467-026-73749-y Source material

Added to your cart

View Cart Checkout
Loading...